Waterfront Wealth Inc. Has $747,000 Position in Lantheus Holdings, Inc. $LNTH

Waterfront Wealth Inc. cut its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 46.8% in the 1st quarter, Holdings Channel.com reports. The firm owned 9,843 shares of the medical equipment provider’s stock after selling 8,675 shares during the quarter. Waterfront Wealth Inc.’s holdings in Lantheus were worth $747,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. M&T Bank Corp bought a new position in Lantheus in the fourth quarter valued at approximately $370,950,000. Farallon Capital Management LLC increased its position in shares of Lantheus by 56.1% during the fourth quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock worth $361,199,000 after acquiring an additional 1,950,252 shares in the last quarter. Norges Bank acquired a new stake in shares of Lantheus during the fourth quarter worth $76,197,000. Freestone Grove Partners LP raised its holdings in shares of Lantheus by 4,114.8% during the fourth quarter. Freestone Grove Partners LP now owns 608,526 shares of the medical equipment provider’s stock worth $40,497,000 after acquiring an additional 594,088 shares during the period. Finally, Summit Street Capital Management LLC bought a new stake in Lantheus in the 4th quarter valued at $26,997,000. 99.06% of the stock is owned by institutional investors.

Lantheus Stock Down 0.3%

Lantheus stock traded down $0.35 during mid-day trading on Friday, reaching $105.64. The company’s stock had a trading volume of 942,439 shares, compared to its average volume of 903,660. The company has a market capitalization of $6.88 billion, a price-to-earnings ratio of 25.46 and a beta of -0.06. Lantheus Holdings, Inc. has a 12 month low of $47.25 and a 12 month high of $111.86. The business’s 50 day simple moving average is $100.71 and its 200 day simple moving average is $82.90. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.64 and a current ratio of 2.83.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, topping the consensus estimate of $1.25 by $0.21. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The firm had revenue of $377.33 million for the quarter, compared to analysts’ expectations of $354.48 million. During the same period in the previous year, the firm posted $1.53 EPS. The company’s revenue for the quarter was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, research analysts anticipate that Lantheus Holdings, Inc. will post 4.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Jefferies Financial Group reaffirmed a “buy” rating and issued a $110.00 target price on shares of Lantheus in a research note on Tuesday, March 17th. The Goldman Sachs Group restated a “neutral” rating and issued a $94.00 price target on shares of Lantheus in a report on Thursday, May 7th. Wall Street Zen cut Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. William Blair reiterated an “outperform” rating on shares of Lantheus in a report on Tuesday, March 17th. Finally, Citizens Jmp reissued a “market outperform” rating and issued a $115.00 target price on shares of Lantheus in a research report on Monday, June 29th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $108.29.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.